1. Home
  2. IDN vs BOLD Comparison

IDN vs BOLD Comparison

Compare IDN & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellicheck Inc.

IDN

Intellicheck Inc.

HOLD

Current Price

$2.41

Market Cap

56.5M

Sector

Technology

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$2.64

Market Cap

60.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDN
BOLD
Founded
1994
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
56.5M
60.8M
IPO Year
2014
2024

Fundamental Metrics

Financial Performance
Metric
IDN
BOLD
Price
$2.41
$2.64
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
★ $7.33
$4.00
AVG Volume (30 Days)
★ 297.2K
107.1K
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 220.00
32.47
EPS
★ 0.06
N/A
Revenue
★ $4,433,454.00
N/A
Revenue This Year
$12.54
N/A
Revenue Next Year
$15.32
N/A
P/E Ratio
$40.00
★ N/A
Revenue Growth
★ 23.21
N/A
52 Week Low
$2.32
$0.96
52 Week High
$9.08
$3.16

Technical Indicators

Market Signals
Indicator
IDN
BOLD
Relative Strength Index (RSI) 31.57 39.30
Support Level N/A $2.39
Resistance Level $3.00 $2.79
Average True Range (ATR) 0.09 0.09
MACD 0.02 -0.03
Stochastic Oscillator 18.02 18.57

Price Performance

Historical Comparison
IDN
BOLD

About IDN Intellicheck Inc.

Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company includes solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: